KCNH2 and torsades de pointes: At later development stage, a higher threshold (lower false negative rate/higher sensitivity) could be applied to determine which drugs have low probability of hERG block-mediated TdP liability, and which ones may have enough concern and warrant the use of more comprehensive models for accurate TdP risk assessment.